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Summary
Background Recurrence of tuberculosis after treatment makes management diﬃ  cult and is a key factor for determining 
treatment eﬃ  cacy. Two processes can cause recurrence: relapse of the primary infection or re-infection with an 
exogenous strain. Although re-infection can and does occur, its importance to tuberculosis epidemiology and its 
biological basis is still debated. We used whole-genome sequencing—which is more accurate than conventional 
typing used to date—to assess the frequency of recurrence and to gain insight into the biological basis of re-infection.
Methods We assessed patients from the REMoxTB trial—a randomised controlled trial of tuberculosis treatment that 
enrolled previously untreated participants with Mycobacterium tuberculosis infection from Malaysia, South Africa, and 
Thailand. We did whole-genome sequencing and mycobacterial interspersed repetitive unit-variable number of 
tandem repeat (MIRU-VNTR) typing of pairs of isolates taken by sputum sampling: one from before treatment and 
another from either the end of failed treatment at 17 weeks or later or from a recurrent infection. We compared the 
number and location of SNPs between isolates collected at baseline and recurrence.
Findings We assessed 47 pairs of isolates. Whole-genome sequencing identiﬁ ed 33 cases with little genetic distance 
(0–6 SNPs) between strains, deemed relapses, and three cases for which the genetic distance ranged from 1306 to 
1419 SNPs, deemed re-infections. Six cases of relapse and six cases of mixed infection were classiﬁ ed diﬀ erently by 
whole-genome sequencing and MIRU-VNTR. We detected ﬁ ve single positive isolates (positive culture followed by at 
least two negative cultures) without clinical evidence of disease.
Interpretation Whole-genome sequencing enables the diﬀ erentiation of relapse and re-infection cases with greater 
resolution than do genotyping methods used at present, such as MIRU-VNTR, and provides insights into the biology 
of recurrence. The additional clarity provided by whole-genome sequencing might have a role in deﬁ ning endpoints 
for clinical trials.
Funding Wellcome Trust, European Union, Medical Research Council, Global Alliance for TB Drug Development, 
European and Developing Country Clinical Trials Partnership.
Introduction
Tuberculosis is a chronic pulmonary infection that can 
recur after initial successful treatment. The prevalence of 
recurrent tuberculosis worldwide is thought to be low; 
WHO has estimated that, of the 6·2 million cases of 
tuberculosis in 2011, roughly 5% were recurrences.1 
Recurrence can happen by two means: relapse of the 
primary infection that treatment has failed to eradicate or 
re-infection with an unrelated exogenous strain. 
Molecular genotyping techniques—such as IS6110 
ﬁ ngerprinting, myco bacterial interspersed repetitive 
unit-variable number of tandem repeat (MIRU-VNTR), 
and spoligotyping—are based on the detection of 
diﬀ erences in the number or location of particular 
genetic sequences or signatures and have enabled 
researchers to assess the proportion of recurrences 
caused by re-infection.
Both mixed infections (the presence of more than one 
strain)2 and exogenous re-infection occur often and the 
rate of re-infection is related to tuberculosis infection 
density.3 In high incidence regions—eg, Cape Town, 
South Africa—re-infection is common, with one study 
classifying 77% of recurrences as re-infection.4 Higher 
rates of re-infection are associated with HIV infection.5 
For example, in India, an estimated 88% of recurrences 
in HIV-positive patients were caused by re-infection 
compared with only 9% in HIV-negative patients.6
The resolution of established molecular typing 
techniques is limited by the highly monomorphic nature 
of the Mycobacterium tuberculosis population. Whole-
genome sequencing of M tuberculosis enables isolates to 
be diﬀ erentiated with much greater resolution, providing 
insights into evolution,7 epidemiology,8,9 and mutation 
rate.9–11 To date, whole-genome evolutionary analyses 
have been limited because of the diversity of proline–
glutamate (PE) and proline–proline–glutamate (PPE) 
gene families. Genes in these families have been 
excluded from analyses because of their high guanine 
Lancet Respir Med 2013; 
1: 786–92 
Published Online
November 21, 2013
http://dx.doi.org/10.1016/ 
S2213-2600(13)70231-5
See Comment page 759 
Copyright © Bryant et al. Open 
Access article distributed under 
the terms of CC BY
Wellcome Trust Sanger 
Institute, Hinxton, UK 
(J M Bryant BSc, S R Harris PhD, 
Prof J Parkhill PhD, 
S D Bentley PhD); Division of 
Pulmonology, University of 
Cape Town, Cape Town, South 
Africa (Prof R Dawson MD); 
DST/NRF Centre of Excellence 
for Biomedical Tuberculosis 
Research, MRC Centre for 
Molecular and Cellular Biology, 
Division of Molecular Biology 
and Human Genetics, 
Stellenbosch University, 
Tygerberg, South Africa 
(Prof A H Diacon MD, 
Prof P van Helden PhD); South 
African Medical Research 
Council and KwaZulu Research 
Institute for TB and HIV, 
Durban, South Africa 
(A Pym MD); Institute of 
Respiratory Medicine, Kuala 
Lumpur, Malaysia 
(A A Mahayiddin FRCP); Chest 
Disease Institute, Muang, 
Nothaburi, Thailand 
(C Chuchottaworn MD); Clinical 
HIV Research Unit, Helen Joseph 
Hospital, Westdene, 
Johannesburg, South Africa 
(Prof I M Sanne MMed PhD); 
Madibeng Centre for Research, 
Brits, South Africa (C Louw MB); 
Radboud MD University 
Nijmegen Medical Centre/UCCZ 
Dekkerswald, Nijmegen, 
Netherlands (M J Boeree MD); 
Department of Infectious 
Diseases and Tropical Medicine, 
Klinikum, Ludwig-Maximilians-
University, Munich, Germany 
(Prof M Hoelscher FRCP); DZIF 
German Centre for Infection 
Research, Munich, Germany 
Articles
www.thelancet.com/respiratory   Vol 1   December 2013 787
and cytosine content and their repetitive nature, which 
make sequencing and genome assembly diﬃ  cult. 
Despite accounting for almost 10% of the coding capacity 
of the genome,12 the function of PE and PPE genes is 
unknown. There is a high degree of diversity between 
isolates of M tuberculosis, for both individual PE and PPE 
genes13,14 and the gene families as a whole.15 Exclusion of 
these genes in previous analyses might have resulted in 
underestimates of genetic diversity. PE and PPE are 
probably involved in interactions with the human 
immune system, and perhaps immune evasion. 
However, no direct evidence exists of within-patient 
antigenic variation of these genes.
We investigated the use of whole-genome sequencing 
to distinguish the source of relapse in patients infected 
with M tuberculosis.
Methods
Study design and participants
We analysed the ﬁ rst 50 paired isolates available 
from participants in the multicentre REMoxTB drug 
trial (registered with ClinicalTrials.gov, number 
NCT00864383). These pairs consisted of an initial isolate 
and second isolate from after week 17 of treatment, taken 
by sputum sample from patients with relapse or 
bacteriological failure. As described previously,16 eligible 
patients were adults diagnosed with previously untreated, 
drug-sensitive, smear-positive, pulmonary tuberculosis 
without severe comorbidities. HIV-positive patients with 
a CD4 count below 250 cells per μL or those already 
taking antiretroviral treatment were excluded. All 
participants were treated for tuberculosis for 26 weeks 
with one of three regimens lasting 4 months or 6 months 
and containing rifampicin, isoniazid, ethambutol, 
pyrazinamide, moxiﬂ oxacin, or placebo. The total 
observation period was 18 months, including treatment 
and follow-up. All patients, researchers, and staﬀ 
involved were masked to treatment allocation. The study 
was approved by local and national ethics committees 
and regulatory authorities.16 Participants provided 
informed consent. Consent was written unless the 
participant was illiterate, in which case witnessed oral 
consent was used. Strains and clinical data presented in 
this report were used according to the approvals and 
consent procedures of REMoxTB.
Procedures
We assessed clinically relevant cases—ie, patients with 
treatment failure or recurrent disease. We diﬀ erentiated 
between treatment failure and recurrence by reviewing 
complete case history, including all culture results and all 
clinical information available. Cases were deﬁ ned as 
single isolated positive culture when a positive culture 
was followed by at least two negative cultures without re-
treatment having been initiated by a physician and the 
patient remaining free of symptoms throughout the 
remainder of follow-up.
We took a 10 μL loop from a Löwenstein-Jensen 
medium slope and, after heat killing, extracted DNA ﬁ rst 
by digestion with lysozyme and proteinase K, solubilised 
by detergents sodium dodecyl sulphate and cetrimonium 
bromide, followed by chloroform isopropanol extraction.17 
We did MIRU-VNTR by ampliﬁ cation of 24 loci, as 
described previously.18
We constructed sequencing libraries in two multiplex 
pools of 62 and 38 isolates with each isolate uniquely 
tagged. The DNA polymerase KAPA HiFi 
(KapaBiosystems, Woburn, MA, USA) provides good 
coverage for regions of the genome with high guanine 
and cytosine content,19 so we used it to generate all the 
sequencing libraries in our study. The pools were 
subjected to paired-end sequencing on a single lane of 
the HiSeq platform (Illumina, San Diego, CA, USA) 
with a read length of 100 base pairs. Reads are deposited 
in the European Nucleotide Archive (accession number 
ERP001037).
For analysis of single nucleotide polymorphisms 
(SNPs), we mapped reads to a corrected version of the 
H37Rv reference genome20 with SMALT (version 0.5.8) 
and identiﬁ ed SNPs as previously described.11,21 We built 
a maximum likelihood phylogenetic tree based on the 
variable positions with RAxML (version 7.0.4).22 SNPs 
between recurrence pairs were recorded only if the base 
in both isolates passed quality checks.11,21 Any SNPs in the 
PE and PPE genes that diﬀ ered between the relapse pairs 
were discounted. Diﬀ erences between the relapse pairs 
were checked manually against the raw sequencing data. 
Mixed-base positions were identiﬁ ed as sites where more 
than one base had been identiﬁ ed in a single sample, 
where each allele was supported by at least 5% of reads 
(minimum read depth of four). We included only 
positions without strand bias (p>0·05),23 that had 
coverage within the normal range, that had mapping 
quality score greater than 50, and that had base quality 
scores greater than 30. These cutoﬀ s accord with those 
that would be applied to high quality SNPs and were 
prespeciﬁ ed to minimise false positives.21 Sites within 
200 base pairs of other heterozygous sites were 
discounted because of the possibility that they might 
have been caused by a mapping error. 
Mapping PE and PPE genes is prone to errors and can 
result in artifacts because sequences are not unique; 
therefore, an assembly approach is needed. We analysed 
the genes with de-novo assembly using Velvet (1.2.03).24 
SNPs, insertions, and deletions were identiﬁ ed from 
pairs of isolates from relapse patients and manually 
assessed. We mapped raw sequence reads back onto the 
assembly to identify possible errors (appendix).
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publication. JMB, SRH, SDB, and JP had access to all 
the raw genomics data, SHG had access to all the 
clinical data, SHG, TDMcH, ALCB, RDH, LW, and SM 
had access to the microbiological data.
Results
We did whole-genome sequencing for paired samples 
from 50 patients (11 of whom were HIV seropositive). 
None of the isolates showed resistance to study drugs, as 
measured by mycobacterial growth indicator tube 
susceptibility testing or genome sequence. For 96 of the 
samples (47 patient-pairs plus two pairs where a result was 
not obtained from one sample and another pair where 
both isolates failed to sequence; ﬁ gure 1) we obtained an 
average coverage of 120-fold. We excluded four samples 
because of poor coverage or contamination with a non-
mycobacterial source (ﬁ gure 1). Based on the 10 354 
variable positions, we built a maximum likelihood 
phylogeny, which showed four globally recognised lineages 
(appendix).
We classed a pair as a mixed infection if one of the 
isolates had more than 80 heterogeneous base pairs. 
Discounting mixed infections, diﬀ erences of SNPs 
between the relapse and re-infection pairs was large 
(ﬁ gure 2), with a clear distinction between pairs with 
little diﬀ erence (≤6 SNPs), and those with a high 
diﬀ erence (≥1306). Walker and colleagues report9 that 
within-patient diversity does not generally exceed 
14 SNPs, with most patients having fewer than ﬁ ve 
diﬀ erences between initial and later isolates.9 Thus, we 
are conﬁ dent that pairs with few diﬀ erences are relapses, 
and those with many diﬀ erences are re-infection.
We identiﬁ ed relapses in 33 of 47 patients (70%; table 1), 
with pairs diﬀ ering by a mean of 0·47 SNPs (SD 1·21) 
and most (n=27) having no polymorphisms. Three pairs 
(7%)—which all had more than 1306 diﬀ erences—were 
re-infections. All three re-infections involved isolates 
belonging to diﬀ erent lineages: either the Euro-American 
or east Asian type. The mean SNP distance between the 
re-infection isolates was 1355, which is greater than the 
mean pairwise distance between all isolates in the whole 
dataset (972).
For 87 samples, we identiﬁ ed fewer than 40 hetero-
geneous sites across the genome, which was probably 
caused by mapping error. However, for seven pairs, more 
than 80 sites were identiﬁ ed (appendix) and were manually 
inspected for mixed bases at lineage-deﬁ ning positions, or 
where SNPs had been identiﬁ ed in the other isolate of the 
pair.25 Six patients had evidence of a mixed infection, of 
whom four were mixed in the ﬁ rst sample of the patient’s 
pair. The isolates were heterogeneous at positions where 
an SNP was identiﬁ ed in the second sample, indicating 
that the initial sample contained a strain found in the 
second isolate plus a sequence from another lineage. Two 
patients had evidence of two distinct strains only in the 
second isolate (appendix), one of which was the same 
strain as in the initial sample, which could be interpreted 
as relapse and superinfection. An additional sample also 
had evidence of a mixed population, but was deﬁ ned 
clinically as a single isolated positive.
Five cases were deﬁ ned clinically as single isolated 
positives. These cases had been deﬁ ned by whole-genome 
33 pairs relapse 3 pairs re-infection 5 single isolated positives
4 with diﬀerent strain 1 identical strain
50 pairs of isolates selected
3 pairs excluded
    1 both isolates failed
    1 second isolate contaminated with non-mycobacteria
    1 one isolate failed
47 pairs assessed
6 pairs mixed infection
Figure 1: Distribution of the case outcomes for study patients based on sequencing quality data, sequence 
comparison, and clinical evaluation
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Figure 2: Pair-wise distances between pairs of isolates from the same patient
For each patient pair, the calculated pair-wise distance is based on the number of 
high quality base diﬀ erences between the samples.
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sequencing as a diﬀ erent strain (n=3), a mixed infection 
(n=1), and relapse (n=1). The relapse strain diﬀ ered by 
three single nucleotide polymorphisms, suggesting that 
this case was a true relapse and not cross-contamination.
Table 2 shows the diﬀ erent results obtained with 
24 locus MIRU-VNTR typing and whole-genome 
sequencing. The three pairs identiﬁ ed as re-infection by 
whole-genome sequencing diﬀ ered by 3–13 loci. As 
expected most relapse cases (n=27) had an identical 
MIRU-VNTR type, but six diﬀ ered by one or more loci 
(ﬁ gure 3). Six cases that were identiﬁ ed as possible mixed 
infections by whole-genome sequencing were identiﬁ ed 
as re-infections (n=4) or relapse (n=2) by MIRU-VNTR.
Of 18 SNPs identiﬁ ed between the relapse pairs, 
13 were non-synonymous. These mutations were in 
genes that encode proteins with various functions 
(appendix); for two cases, the genes were involved in 
survival during oxidative stress. We identiﬁ ed two 
insertion–deletion diﬀ erences that resulted in frame-
shifts within protein-coding regions.
Use of Kappa HiFi improved coverage of PE and PPE gene 
families by an average of 27% in all subfamilies compared 
with the standard protocol (appendix). Overall, 86% of genes 
(82% PPE, 97% non-PGRS PE, 84% PE–PGRS) were 
assembled, which enabled 82% of genes to be compared 
between the 24 pairs (appendix). For the 24 pairs for which 
the PE and PPE genes were assembled, we detected no 
additional variants in these regions (appendix).
Discussion
Our study is the ﬁ rst to our knowledge to assess whole-
genome sequencing in the context of relapse and re-
infection with tuberculosis. Clinical trials for tuberculosis 
MIRU-VNTR designation
Relapse Re-infection
Relapse (n=33) 27 6
Mixed infection (n=6) 2 4
Re-infection (n=3) 0 3
Single isolated positive (n=5*) 0 5
MIRU-VNTR=mycobacterial interspersed repetitive unit-variable number of 
tandem repeat. *Includes one isolate identiﬁ ed as a relapse (three single 
nucleotide polymorphisms) and one sample that is mixed according to whole-
genome sequencing.
Table 2: Designation of recurrence strains by MIRU-VNTR, by 
whole-genome sequencing designation
Time between 
episodes (weeks)
SNP distance Site
Relapses
4 48 6 Stellenbosch, SA
5 26 0 Stellenbosch, SA
6 26 0 Cape Town, SA
7 36 0 Stellenbosch, SA
9 26 0 Stellenbosch, SA
11 26 0 Stellenbosch, SA
12 36 0 Stellenbosch, SA
13 36 1 Stellenbosch, SA
16 26 0 Cape Town, SA
17 26 0 Cape Town, SA
18 48 0 Stellenbosch, SA
19 36 0 Stellenbosch, SA
20 48 0 Stellenbosch, SA
21 36 1 Stellenbosch, SA
22 26 0 Cape Town, SA
24 36 0 Cape Town, SA
25 48 0 Cape Town, SA
26 36 0 Cape Town, SA
27 36 0 Stellenbosch, SA
28 36 0 Stellenbosch, SA
29 36 0 Cape Town, SA
30 26 0 Stellenbosch, SA
31 26 0 Stellenbosch, SA
32 26 0 Durban, SA
33 60 0 Durban, SA
34 36 0 Durban, SA
40 36 0 Durban, SA
41 28 2 Johannesburg, SA
43 36 1 Brits, SA
44 48 0 Brits, SA
47 17 0 Kuala Lumpur, MY
48 36 0 Nonthaburi, TH
49 36 2 Nonthaburi, TH
Re-infections
10 48 1419 Cape Town, SA
14 60 1340 Cape Town, SA
35 17 1306 Durban, SA
(Continues in next column)
Time between 
episodes (weeks)
SNP distance Site
(Continued from previous column)
Mixed infections
2 36 64 Cape Town, SA
8 26 48 Stellenbosch, SA
23 36 0 Stellenbosch, SA
42 37 1 Brits, SA
45 17 1 Kuala Lumpur, MY
50 36 0 Nonthaburi, TH
Single isolated positives
3 36 3 Stellenbosch, SA
15 26 1364 Stellenbosch, SA
36 28 898 Durban, SA
37 48 1207 Durban, SA
38 60 767 Durban, SA
SNP=single nucleotide polymorphism. MY=Malaysia. SA=South Africa. 
TH=Thailand. 
Table 1: Whole-genome sequencing results and patient information, 
by patient ID
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are based on the assumption of clonal infection. Thus, 
when disease re-occurs, it is assumed to be a relapse and 
this is the primary endpoint for many studies underway 
at present. Spoligotyping,26 insertion sequence typing 
(IS6110),27 and MIRU-VNTR18 have all been used to show 
that re-occurring strains are highly dissimilar, suggesting 
exogenous re-infection.3,4,6 However, these techniques 
lack the resolution needed for more detailed investigation 
of re-infection,28 and the diﬀ erent techniques sometimes 
provide incongruous data.29 The ability to accurately 
distinguish relapse from re-infection is of critical 
importance to understanding tuberculosis epidemiology 
and for choosing endpoints for clinical trials and patient 
management. Our ﬁ ndings provide proof of principle 
that when a patient is infected with a single strain, whole-
genome sequencing can unequivocally distinguish 
relapse and re-infection (panel).
The presence of diﬀ erent numbers of copies of loci in 
recurrence pairs that had no detectable diﬀ erences in 
SNPs, suggests that previous estimates of re-infection 
rates might have been too high, because many studies 
use a cutoﬀ  of one MIRU-VNTR locus.6,30 Variation in the 
MIRU-VNTR loci between isolates diﬀ ering by less than 
ﬁ ve SNPs has also been reported previously.9 Likewise, 
for one pair separated by more than 760 SNPs, we 
detected a diﬀ erence at only one MIRU-VNTR locus. 
Overall, the genetic diversity of relapse and re-infection 
cases overlapped when assessed with MIRU-VNTR loci, 
but were clearly separated when we used whole-genome 
screening. Our data suggest that the relationship between 
the two methods for the rate of variation generated is 
non-linear and that the regular accumulation of SNPs is 
a more reliable marker of genetic relatedness between 
strains.
The diﬀ erent classiﬁ cation of outcome by MIRU-VNTR 
will have a substantial eﬀ ect on interpretation and design 
(particularly sample size) of clinical trials. 18% of cases 
were misclassiﬁ ed as relapse—the primary endpoint in 
many clinical trials—indicating the need to use whole-
genome sequencing to classify these outcomes more 
accurately. Use of whole-genome sequencing will 
determine the endpoint more accurately, which should 
result in smaller sample sizes and reduced costs of 
studies.
During clinical trials of tuberculosis treatment, a single 
strain is usually isolated during patient selection, which 
is assumed to be representative. Although the 
bacteriological methods of our study were focused on the 
isolation of a single strain, six patients had mixed 
infection. Four of these patients would have been 
classiﬁ ed as re-infected using MIRU-VNTR typing alone. 
This high number of mixed infections in endemic areas 
accords with previous ﬁ ndings.2 Additionally, we could 
not always amplify all loci, especially in cases of mixed 
infection. These data suggest that further studies are 
needed using whole-genome sequencing to understand 
how common mixed infection is in diﬀ erent settings and 
its eﬀ ect on the evolution of drug resistance. The 
implication for clinical trials is that more strenuous 
eﬀ orts should be made to identify mixed infection that 
could be incorrectly identiﬁ ed as re-infection. This might 
require sequencing of multiple colonies or non-colony-
puriﬁ ed cultures of multiple samples.
In a previous study,31,32 405 single isolated positive 
samples were identiﬁ ed from 37 429 samples taken from 
2133 patients in four clinical trials with no clinical 
evidence of relapse. Without eﬀ ective typing methods 
available, positive results were ascribed to clerical error, 
cross-contamination, or as arising from the patient’s 
lesions.31 Experiments reported at the same time showed 
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Figure 3: MIRU-VNTR loci diﬀ ering between pairs of isolates from the 
same patient 
(A) Number of loci diﬀ ering between pairs of isolates from the same patient 
with relapse, re-infection, mixed infection, and single isolated positives 
identiﬁ ed by whole genome sequencing. (B) Comparison of diﬀ erences 
detected by whole genome sequence data and MIRU-VNTR; red=relapse, 
blue=re-infection. MIRU-VNTR=mycobacterial interspersed repetitive 
unit-variable number of tandem repeat. 
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that transfer from positive to negative samples occurred 
in 0 of 825 (0%) samples in a laboratory in London and in 
28 of 2165 (1·3%) samples in Kampala.32 Of the ﬁ ve cases 
we identiﬁ ed as single isolated positives, four were 
probably caused by cross-contamination and one 
provides evidence for the ﬁ rst time that positive cultures 
originating from the patient’s own infection can be 
cultured and the patient’s infection resolved without 
further chemotherapy. Cross-contamination is a well-
recognised challenge in mycobacteriology laboratories. It 
occurs in less than 1% of positive samples overall with 
more than half of laboratories achieving a proportion of 
less than 2·5%.32,33 In clinical trials, investigators should 
ensure that adequate molecular methods are used to 
correctly identify the origin of single isolated positive 
samples.
Our ﬁ ndings reaﬃ  rm the high genomic stability 
previously reported9,11 for M tuberculosis in the context of 
transmission, in which the rate of genetic turnover of 
M tuberculosis was 0·3–0·5 SNPs per genome per year. 
Previous studies15 have reported more variation in the PE 
and PPE genes than we detected, but many genes—
particularly those belonging to the PE–PGRS subfamily—
were not included in previous whole-genome sequencing 
studies. We were able to assemble 86% of the PE and 
PPE genes in a set of relapse pairs including 84% of the 
PE–PGRS genes. This shows that diversity in these 
genes—discounted from most previous studies of the 
M tuberculosis genome—can be captured with short 
reads. We detected no variation—ie, SNPs, insertions, or 
deletions—between any of the relapse pairs. The lack of 
diversity in these genes suggests that variation within 
patients is low; indicating that such diversity might not 
be the mechanism of immune escape, as previously 
postulated.15 However, these genes might generate 
diversity over longer timescales or diﬀ erentially regulated 
expression of these genes might enable immune escape.
We have shown that a large phylogenetic distance 
separates re-infection pairs belonging to diﬀ erent 
lineages and distinct from relapse cases. As far as we 
know, this ﬁ nding has not been previously reported, 
probably because of the limitations of earlier genotyping 
technologies, which include high levels of incongruence.29 
This ﬁ nding should be followed up in subsequent studies 
because it implies that re-infection requires the new 
strain to be signiﬁ cantly genetically diﬀ erent to the 
originally infecting strain. If conﬁ rmed, it could indicate 
that re-infection occurs because primary infection does 
not provide suﬃ  cient immune protection against 
distantly related strains, which is of importance for 
future vaccine design.
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Panel: Research in context
Systematic review
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